The Tendyne transcatheter mitral valve implant demonstrated 96% technical success, 6% 30-day mortality, and 72.4% one-year survival in the first 100 patients of an early feasibility study.
The Tendyne transcatheter mitral valve system provides a repositionable and retrievable treatment option for high-risk patients with severe mitral regurgitation or mitral annular calcification.
Mitral valve regurgitation (MR) has a high incidence in the western world, and mortality is high for untreated severe MR. Catheter based repair was introduced with MitraClip in 2003, and some additional devices later came into the market. To expand the transcatheter treatment options for mitral valve disease, the first transcatheter mitral valve implantation (TMVI) was performed by Søndergaard et al. 2012, only 10 years after the first transcatheter aortic valve implantation (TAVI), however, the development has been much slower for the TMVI than for TAVI. From 2012, studies were started for several devices to prove feasibility and safety. However, there were big challenges in valve design; delivery systems and anchoring in addition to anatomical issues (avoid LVOT obstruction and paravalvular leak, big size of annulus). The main valves in studies were CardiaQ (later bought by Edwards Lifesciences, Irvine, United States), Tiara (Neovasc Inc., Richmond, Canada), Twelve (later Intrepid, Medtronic, MN, United States) and Tendyne™ (Abbott, MN, United States). I will focus on the Tendyne™ valve that is the only CE approved transcatheter mitral valve implant. It is available in a large number of sizes and is repositionable and retrievable. The results for the 100 first patients included in the early feasibility study (EFS) at 1 and 2 years are promising. Initially feasible for MR, but further investigations show promising results also for implant in mitral annular calcification.
Gry Dahle (2020) conducted a review in Mitral valve regurgitation. Tendyne transcatheter mitral valve implantation was evaluated. The Tendyne transcatheter mitral valve implant demonstrated 96% technical success, 6% 30-day mortality, and 72.4% one-year survival in the first 100 patients of an early feasibility study.